What’s in Your Water?
The 2026 Federal Drinking Water Outlook Is Fluid.

KEY POLICY INDICATORS

• EPA moved to rescind drinking water limits for four PFAS compounds; PFOA/PFOS compliance extended to 2031
• EPA & HHS jointly placed microplastics and pharmaceuticals on the federal contaminant watch list for the first time (April 2, 2026)
• HHS announced a $144 million STOMP initiative to study and remove microplastics from the human body
• Congress cut $125 million in lead pipe replacement funding from the FY2026 spending bill
• The D.C. Circuit denied EPA’s motion to pause litigation over four PFAS standards (March 2026)
• Water Resources Development Act (WRDA) process expected to begin in Congress in 2026

Safe drinking water sits at the intersection of public health, infrastructure investment, federal regulation, and increasingly national politics. In 2026, the federal government is pulling in multiple directions at once: rolling back some contaminant standards, adding new ones to a research watchlist, cutting infrastructure dollars with one hand, and defending others with the second. For businesses, utilities, states, and advocacy organizations, the challenge is reading what each move signals and what comes next.

The PFAS Picture: A Rule Divided

No issue has dominated federal water policy more than per- and polyfluoroalkyl substances, the “forever chemicals” found in everything from nonstick cookware to firefighting foam. In April 2024, the Biden EPA finalized the first-ever national drinking water standards for six PFAS compounds under the Safe Drinking Water Act. The rule required public water systems to test and comply with maximum contaminant levels (MCLs) by 2029. The Trump administration has since moved to dismantle parts of that framework, and the battle is playing out simultaneously in the regulatory arena and the courts.

EPA has retained and is actively defending the MCLs for PFOA and PFOS, the two most studied and widespread PFAS compounds. However, as tracked by Harvard’s Environmental and Energy Law Program, EPA has announced its intent to rescind the regulatory limits for four others, including PFHxS, PFNA, HFPO-DA (GenX), and a hazard index mixture, arguing for a fresh rulemaking process. Additionally, EPA extended the PFOA and PFOS compliance deadline from 2029 to 2031, citing the logistical challenges facing water systems attempting to complete infrastructure upgrades on the original timeline.

The courts aren’t cooperating cleanly. In February 2026, EPA asked the D.C. Circuit to separate and pause challenges related to the four PFAS it intended to rescind. The court denied that motion in March 2026, meaning litigation over the full PFAS rule continues. As Chemical & Engineering News reported in February, federal action on PFAS is expected to slow this year as midterm election dynamics set in. However, state-level momentum is accelerating to fill the regulatory vacuum, with states across the country moving to enact their own reporting requirements and product restrictions.

For organizations with water infrastructure exposure, the practical reality is this: PFAS reporting requirements under TSCA are moving forward, including a data submission window running from April 13 through October 13, 2026, for most reporting entities.

Microplastics: A New Front Opens

In a joint announcement on April 2, 2026, EPA Administrator Lee Zeldin and HHS Secretary Robert F. Kennedy Jr. unveiled what the administration called a historic step for the Make America Healthy Again movement. For the first time, EPA’s draft Sixth Contaminant Candidate List (CCL 6) includes microplastics and pharmaceuticals as priority contaminant groups, joining PFAS and disinfection byproducts on the agency’s formal watchlist under the Safe Drinking Water Act.

The CCL is a study list, not a regulation. Inclusion signals that a substance warrants serious scientific attention and could eventually lead to rulemaking. Historically, very few contaminants from the list have been formally regulated since the program began in 1996. The CCL 6 draft opens a 60-day public comment period, with finalization expected by November 17, 2026. Simultaneously, EPA released human health benchmarks for 374 pharmaceuticals, offering water utilities a tool to assess risk when drug residues are detected.

On the HHS side, Secretary Kennedy announced a $144 million program called STOMP — Systematic Targeting of Microplastics to be led by ARPA-H, the Advanced Research Projects Agency for Health. The initiative will develop detection tools, map how microplastics move through the body, and ultimately pursue removal strategies. The two-phase program prioritizes research on those at greatest risk, including pregnant people, children, and high-exposure workers.

Environmental groups are divided on the significance of the announcements. Some researchers praised the CCL listing as a meaningful first step. Others, including Earthjustice and Food & Water Watch, argued the moves lack regulatory teeth and pointedly noted that the same administration is simultaneously rolling back PFAS standards and has proposed deep cuts to water infrastructure funding. The Unregulated Contaminant Monitoring Rule (UCMR), a separate and more actionable mechanism, is due to be finalized by the end of 2026, and advocates are pushing EPA to include microplastics in that rule as well.

Lead Pipes: Infrastructure Funding Under Pressure

While emerging contaminants dominate the headlines, the decades-old problem of lead service lines remains a front-burner issue, with a funding fight that cuts to the heart of this Congress’s priorities. The 2021 Bipartisan Infrastructure Law committed $15 billion over five years for lead pipe replacement. FY2026 is the final year of that authorization window, with approximately $3 billion in remaining disbursements slated for this year.

The FY2026 government spending package embedded a $125 million cut to that lead pipe funding, redirecting the dollars to wildland fire management. An earlier Senate framework had proposed cutting $250 million, and the smaller final cut came only after sustained advocacy from environmental groups and members of Congress. In December, Reps. Dingell and Tlaib of Michigan organized a letter signed by 43 colleagues calling for full funding restoration. The Clean Water and Drinking Water State Revolving Funds (the primary federal mechanism for water infrastructure financing) were held at the same level in the final bill, a bipartisan rejection of the administration’s original proposal to cut them by nearly 90 percent.

The fiscal picture is further complicated by a methodological dispute: EPA revised its estimate of lead service lines nationwide from 9 million to 4 million, citing more complete inventory data submitted by states. Critics from the Natural Resources Defense Council argue the revision is methodologically flawed and may be a precursor to justifying further funding reductions. States including Illinois, Michigan, Texas, and New York, which hold the highest concentrations of aging lead infrastructure, face the most direct exposure to any additional cuts.

What Congress Is Watching in the Second Half of 2026

Midterm election dynamics will increasingly shape the legislative appetite for major water policy action through the remainder of the year. That said, several processes are moving with their own momentum. The Water Resources Development Act (WRDA), typically a bipartisan vehicle for water infrastructure priorities, is on track for a 2026 bill, with the House Transportation and Infrastructure Committee’s and Senate Environment and Public Works Committee’s project nomination process having been completed. WRDA has historically moved with broad bipartisan support, making it one of the few reliable legislative windows this cycle.

The EPA’s FY2027 budget request, published April 3, 2026, is expected to re-propose cuts to the State Revolving Funds that Congress already rejected for this year. That sets up another funding fight in the appropriations process. Meanwhile, PFAS litigation will continue to wind through the D.C. Circuit, with any resolution potentially reshaping which federal standards remain legally enforceable by year’s end.

For any organization whose operations, supply chains, or community presence touch water systems, the regulatory framework for what is allowed in America’s drinking water is being actively rewritten throughout 2026.

THE FEROX VIEW

Drinking water policy in 2026 is a study in simultaneous action and retreat. The administration is adding new contaminants to the federal radar while walking back others; holding some infrastructure funding steady while trimming elsewhere. The real policy leverage this year lies at the intersection of WRDA negotiations, UCMR finalization, and the D.C. Circuit’s handling of PFAS litigation. Organizations that engage proactively with Congress, the EPA’s comment processes, and state-level regulators filling federal gaps will be far better positioned than those waiting for a unified federal signal that may not come.